BridgeBio Pharma (BBIO) has drawn fresh attention after recent share price moves, with the stock closing at $84.48 on 6 August 2026. Investors are weighing this level against the company’s longer term return profile.
See our latest analysis for BridgeBio Pharma.
The latest move in BridgeBio Pharma’s share price builds on a 30.61% 90 day share price return and an 81.37% 1 year total shareholder return. However, the 30 day share price return of 1.64% shows some cooling in the very short term.
If BridgeBio Pharma has sharpened your interest in high growth healthcare stories, this is a good moment to broaden your search with 43 healthcare AI stocks
BridgeBio Pharma combines a focused genetic disease pipeline with rapid share price gains over the past year. The real test now is whether that story is already fully reflected in today’s US$84.48 price.
Most Popular Narrative: 237.9% Overvalued
BridgeBio Pharma closed at $84.48, while the most followed narrative pegs fair value much lower at $25. That gap frames the debate around the stock.
The "BridgeBio Commercial Bonanza" is priced for perfection, treating the upcoming Acoramidis launch as an automatic cash cow while ignoring a brutal multi-front commercial dogfight.
Here is why the market is mispricing the structural hurdles for BBIO:
Curious how that $25 fair value is built. The narrative leans on specific revenue growth paths, margin assumptions and a future profit multiple that sharply contrasts with today’s price.
Result: Fair Value of $25 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, BridgeBio Pharma could surprise critics if Acoramidis gains stronger than expected traction, or if other late stage programs hit key milestones sooner than bears anticipate.
Find out about the key risks to this BridgeBio Pharma narrative.
Another View on BridgeBio Pharma’s Valuation
The user narrative suggests BridgeBio Pharma’s fair value is $25 and describes the stock as very stretched at $84.48. Our DCF model indicates a different perspective. It points to a future cash flow value of $302.55, which would instead frame BBIO as heavily undervalued.
These are two valuation frameworks applied to the same stock, yet they lead to very different conclusions. Which set of assumptions do you find more realistic for BridgeBio Pharma’s future cash generation? Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out BridgeBio Pharma for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed messages around BridgeBio Pharma’s valuation can be confusing, so move quickly to review the data first hand and weigh the 2 key rewards and 1 important warning sign.
Looking for more BridgeBio Pharma sized ideas?
If BridgeBio Pharma has you thinking more broadly about opportunities, do not stop here. Use the Simply Wall St screener to uncover other stocks that could fit your portfolio.
- Target potential mispricing by scanning companies that currently appear out of favour yet financially robust through the 51 high quality undervalued stocks.
- Prioritise resilience by checking out the 79 resilient stocks with low risk scores, where companies with steadier risk profiles stand out from more volatile alternatives.
- Get ahead of the crowd by reviewing the screener containing 19 high quality undiscovered gems, which focuses on quality businesses that have not yet attracted broad attention from the market.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com